Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:MEHCQ)

4.400 -0.100 (-2.22%)
Streaming Delayed Price Updated: 10:47 AM EDT, Aug 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MEHCQ

TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets
From 23andMe, Inc.
Via GlobeNewswire
23andMe’s $305M Sale To Co-Founder Wojcicki Approved: California Loses Legal Battle Over DNA Privacy
A U.S. bankruptcy judge ruled that California's appeal to block the deal was unlikely to succeed, rejecting claims that the sale violated state genetic privacy laws. 
Via Stocktwits
Topics Bankruptcy
23andMe Co-Founder Anne Wojcicki Wins Back Company In $305M Deal, Beating Regeneron’s Bid
The deal encompasses 23andMe’s core genome testing service, research operations, and Lemonaid Health, with TTAM set to relaunch the company as a nonprofit organization committed to upholding existing... 
Via Stocktwits
Topics Bankruptcy
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation
From 23andMe, Inc.
Via GlobeNewswire
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
From 23andMe, Inc.
Via GlobeNewswire
23andMe Angles For A Bigger Regeneron Bid As Ex-CEO Steps Up With A Better Offer
Regeneron previously won 23andMe at auction. But now the company wants to reopen bidding with an offer from its former CEO. 
Via Investor's Business Daily
Topics Bankruptcy Lawsuit
23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
From 23andMe, Inc.
Via GlobeNewswire
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
From 23andMe, Inc.
Via GlobeNewswire
Options Corner: Why Boring IBM May Be Ideal Tech Play To Ride Economic Chop
While "Big Blue" may be boring, its resilience to macro pressures and sustained market downturns makes IBM stock a compelling idea. 
Via Benzinga
23andMe Provides Update Regarding Court-Supervised Sale Process
From 23andMe, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.